MedTrace Logo

Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans

NCT06940895 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-11-28

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the safety and efficacy of Sirolimus 0.2% topical gel for patients with Acanthosis Nigricans

Conditions

  • Acanthosis Nigricans

Interventions

DRUG

Sirolimus 0.2%

sirolimus 0.2% gel

Sponsors & Collaborators

  • Nobelpharma

    collaborator INDUSTRY

  • Narrows Institute for Biomedical Research

    lead OTHER

Principal Investigators

  • Jared Jagdeo, MD MS · SUNY Downstate Health Sciences University Department of Dermatology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2025-07-08
Completion
2025-07-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06940895 on ClinicalTrials.gov